임플란트 모니터링 소프트웨어 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the implant monitoring software market size is projected to expand from USD 2.31 billion in 2025 and USD 2.53 billion in 2026 to USD 4.30 billion by 2031, registering a CAGR of 11.18% between 2026 to 2031.

This report is Segmented by Product Type (Manufacturer-Native Monitoring Platforms, and More), Monitoring Modality (CIEDs, Loop Recorders, and More), Application (Heart Failure Monitoring, and More), End User (Hospitals, and More), Deployment Model (Cloud SaaS, On-Premise, Hybrid), and Geography (North America, Europe, APAC, MEA, South America).

Global Implant Monitoring Software Market Trends and Insights

Expansion of the Implanted Cardiac Device Base

The growing base of implanted cardiac devices creates recurring demand for the implant monitoring software market. More than 2.5 million cardiac implantable electronic devices are implanted each year globally. Implantable cardioverter-defibrillators and cardiac resynchronization therapy devices have also been growing by 5-6% annually in unit terms, supported partly by broader preventive use in heart failure patients with reduced ejection fraction. Each implant requires years of follow-up transmissions, so the active monitoring population builds more quickly than annual procedure totals suggest. Device replacements from aging battery cohorts add to the workload while newer implants enter their own monitoring schedules. The 2023 HRS, EHRA, APHRS, and LAHRS consensus allows stable patients on continuous remote monitoring to have in-person visits as far as 24 months apart, extending the period in which software supports routine follow-up.

Rising Chronic Disease and Aging-Patient Monitoring Needs

Aging populations are increasing the number of patients who may need cardiac or neuromodulation implants and continuing follow-up. Adults with implanted cardiac devices often have diabetes, hypertension, atrial fibrillation, or several of these conditions at the same time. This raises the value of platforms that can bring together cardiac, activity, and other patient signals for the care team. The implant monitoring software market therefore benefits when providers need a fuller view of changing patient status rather than a single device reading. HeartLogic is an example of a multiparametric tool used in this setting, with reported sensitivity of 70% for impending heart failure events within a 34-day detection window. Such tools can help clinicians recognize changes earlier, although their usefulness in the implant monitoring software market still depends on clinical review and clear care pathways.

Cybersecurity, Privacy, and Connected-Device Liability

Wireless connectivity allows remote follow-up, but it also increases cybersecurity and privacy responsibilities. The FDA's June 2025 guidance on medical-device cybersecurity describes the quality-system considerations and premarket submission content expected for relevant devices. The February 2026 Quality Management System Regulation transition aligned U.S. device quality requirements with ISO 13485:2016, increasing the documentation work for software suppliers. European deployments must also address patient consent, data residency, and cross-border handling of transmitted information. These requirements can place a heavier burden on smaller vendor-neutral providers that do not have the compliance resources of large device manufacturers. The implant monitoring software market must therefore compete on reliable security practices as well as workflow and analytics features.

Other drivers and restraints analyzed in the detailed report include:

1. Shift From In-Person Follow-Up to Remote Care and Reimbursement-Linked Monitoring
2. Uneven Reimbursement and Budget Ownership Across Care Settings

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Manufacturer-native monitoring platforms held 42.3% of the implant monitoring software market share in 2025. Their position reflects direct access to device telemetry, established clinician relationships, and integration with proprietary programming workflows. Many clinics have built their processes around these platforms over years of use. Replacing a familiar system can create training, workflow, and contractual costs for providers. This installed base gives manufacturer-native platforms a durable advantage in the implant monitoring software market. It also explains why device connectivity alone remains a meaningful competitive feature for large manufacturers.

Post-implant care-management and real-world evidence platforms are projected to grow at a 12.5% CAGR through 2031. These platforms address demand for structured evidence after implantation and for data that supports patient follow-up. CMS coverage for implantable pulmonary artery pressure sensors requires participation in approved evidence-development studies, making organized data collection part of the coverage pathway. Vendor-neutral systems can also reduce the burden on multi-manufacturer clinics that otherwise use separate portals from Abbott, Boston Scientific, Medtronic, and BIOTRONIK. Post-market surveillance tools gain relevance as regulators and providers pay closer attention to device performance after approval. Orthopedic recovery platforms are also emerging as sensorized implants begin producing long-term data on gait, step count, and range of motion.

Implantable cardiac electronic devices accounted for 58.4% of the implant monitoring software market size by monitoring modality in 2025. Pacemakers, ICDs, and cardiac resynchronization devices have a large established base and require regular interrogation and alert management. Their software ecosystem includes rhythm detection, battery tracking, lead monitoring, and multiparametric heart failure indices. In the United States, established billing pathways for remote cardiac-device services support continuing software use. CIEDs remain the core modality because their clinical and administrative workflows have had time to mature. The wide range of device data also encourages continued development of analytic and triage features in the implant monitoring software market.

Implantable hemodynamic sensors are forecast to grow at a 12.1% CAGR through 2031. Evidence from CardioMEMS data has linked early pulmonary artery pressure reduction within 90 days of implantation with improved long-term survival among Medicare beneficiaries with heart failure. The CMS coverage determination effective January 13, 2025, links coverage for implantable pulmonary artery pressure sensors with CMS-approved evidence development. This makes software that captures and organizes monitoring information important to the care and coverage process. Loop recorders continue to gain use as atrial fibrillation detection expands. Neuromodulation devices present a newer opportunity, as BIOTRONIK's spinal cord stimulation platform collects more than 200 patient data points each day.

Complete Report Scope:

• By Product Type
  • Manufacturer-Native Monitoring Platforms
  • Vendor-Neutral CIED Management Platforms
  • Orthopedic Implant Recovery and Activity Analytics Platforms
  • Implantable Hemodynamic and Specialty-Monitoring Platforms
  • Post-Implant Care-Management and Real-World-Evidence Platforms
  • Post-Market Surveillance and Implant-Vigilance Software
• By Monitoring Modality
  • Implantable Cardiac Electronic Devices
  • Insertable and Implantable Loop Recorders
  • Implantable Hemodynamic Sensors
  • Sensorized Orthopedic Implants
  • Implantable Glucose and Metabolic Monitors
  • Implantable Neuromodulation and Neuromonitoring Devices
• By Application
  • Arrhythmia, Battery, and Lead Surveillance
  • Heart-Failure and Hemodynamic Monitoring
  • Post-Implant Recovery and Functional-Mobility Monitoring
  • Chronic Disease and Physiologic Monitoring
  • Remote Programming, Interrogation, and Follow-Up
  • Patient Connectivity, Engagement, and Adherence
  • Billing, Reimbursement, and Clinic Workflow Management
  • Post-Market Safety, Recall, and Performance Surveillance
• By End User
  • Hospitals and Academic Medical Centers
  • Specialty and Device Clinics
  • Ambulatory Surgery Centers
  • Home Healthcare Providers
  • Implant Manufacturers and Clinical-Operations Teams
  • Research Organizations and Contract Research Organizations
• By Deployment Model
  • Cloud-Based Software as a Service
  • On-Premise and Private-Cloud Deployments
  • Hybrid Deployments
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.1% of the implant monitoring software market share in 2025. The region benefits from a mature cardiac implant base, established remote-monitoring workflows, and a concentration of manufacturer-native and vendor-neutral platform providers. U.S. providers have well-developed pathways for remote CIED follow-up, which supports regular use of monitoring software. The region is also important for sensorized orthopedic implants. Zimmer Biomet's Persona IQ smart knee uses Canary Medical sensing technology and the mymobility Care Management platform to provide postoperative kinematic information. Canada and Mexico are smaller within the regional total, although concern about avoidable heart failure readmissions is encouraging attention to remote care models.

Europe is the second-largest geography in the supplied analysis. Germany has a comparatively advanced framework for remote CIED management, reinforced by the July 2025 GOP 40909 code for outpatient telemonitoring transmitters. The United Kingdom, France, and Nordic countries have functional tariff structures for remote CIED management. Italy reimburses remote management in 10 of 20 regions, while Poland and Bulgaria do not have a tariff. This uneven funding means software vendors must support different implementation and payment conditions across European markets. EU requirements for medical-device software and personal data can also raise entry requirements for AI-enabled solutions.

Asia-Pacific is forecast to grow at a 12.7% CAGR through 2031. China has a large aging cardiovascular population and public hospitals are increasing their use of digital health infrastructure. India is identified in the supplied material as the fastest-growing country in the region for heart failure software adoption, supported by healthcare infrastructure, private hospital investment, and telehealth policy. Japan's regulatory environment is relevant to software updates for medical devices, while South Korea and Australia are comparatively mature regional settings. The Middle East, South America, and Africa remain earlier-stage adoption areas in the implant monitoring software market. Brazil and Argentina have institutional capacity for CIED monitoring, but public reimbursement remains limited. GCC states are investing in tertiary cardiac centers, creating an emerging customer base for enterprise CIED platforms.

1. Abbott Laboratories
2. Medtronic
3. Boston Scientific
4. BIOTRONIK
5. MicroPort
6. Implicity
7. Vector Remote Care
8. Canary Medical
9. Zimmer Biomet
10. Stryker
11. Smiths Group
12. LifeOmic
13. Welkin Health
14. Koninklijke Philips
15. Veeva Systems
16. Castor
17. Bioexcel Life Sciences
18. NeuroPace
19. CVRx, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expansion of the Implanted Cardiac Device Base
  • 4.2.2 Rising Chronic Disease and Aging-Patient Monitoring Needs
  • 4.2.3 Shift From In-Person Follow-Up to Remote Care and Reimbursement-Linked Monitoring
  • 4.2.4 AI-Based Alert Triage and Workflow Automation
  • 4.2.5 Vendor-Neutral Interoperability for Multi-Brand Implant Clinics, Under-Reported
  • 4.2.6 Objective Recovery Metrics From Sensorized Orthopedic Implants, Under-Reported
• 4.3 Market Restraints
  • 4.3.1 Cybersecurity, Privacy, and Connected-Device Liability
  • 4.3.2 Uneven Reimbursement and Budget Ownership Across Care Settings
  • 4.3.3 False Positives, Alert Fatigue, and Clinical Capacity Constraints
  • 4.3.4 Implant-Specific Data Silos and Limited Evidence for Non-Cardiac Workflows, Under-Reported
• 4.4 Value and Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS, VALUE AND VOLUME

• 5.1 By Product Type
  • 5.1.1 Manufacturer-Native Monitoring Platforms
  • 5.1.2 Vendor-Neutral CIED Management Platforms
  • 5.1.3 Orthopedic Implant Recovery and Activity Analytics Platforms
  • 5.1.4 Implantable Hemodynamic and Specialty-Monitoring Platforms
  • 5.1.5 Post-Implant Care-Management and Real-World-Evidence Platforms
  • 5.1.6 Post-Market Surveillance and Implant-Vigilance Software
• 5.2 By Monitoring Modality
  • 5.2.1 Implantable Cardiac Electronic Devices
  • 5.2.2 Insertable and Implantable Loop Recorders
  • 5.2.3 Implantable Hemodynamic Sensors
  • 5.2.4 Sensorized Orthopedic Implants
  • 5.2.5 Implantable Glucose and Metabolic Monitors
  • 5.2.6 Implantable Neuromodulation and Neuromonitoring Devices
• 5.3 By Application
  • 5.3.1 Arrhythmia, Battery, and Lead Surveillance
  • 5.3.2 Heart-Failure and Hemodynamic Monitoring
  • 5.3.3 Post-Implant Recovery and Functional-Mobility Monitoring
  • 5.3.4 Chronic Disease and Physiologic Monitoring
  • 5.3.5 Remote Programming, Interrogation, and Follow-Up
  • 5.3.6 Patient Connectivity, Engagement, and Adherence
  • 5.3.7 Billing, Reimbursement, and Clinic Workflow Management
  • 5.3.8 Post-Market Safety, Recall, and Performance Surveillance
• 5.4 By End User
  • 5.4.1 Hospitals and Academic Medical Centers
  • 5.4.2 Specialty and Device Clinics
  • 5.4.3 Ambulatory Surgery Centers
  • 5.4.4 Home Healthcare Providers
  • 5.4.5 Implant Manufacturers and Clinical-Operations Teams
  • 5.4.6 Research Organizations and Contract Research Organizations
• 5.5 By Deployment Model
  • 5.5.1 Cloud-Based Software as a Service
  • 5.5.2 On-Premise and Private-Cloud Deployments
  • 5.5.3 Hybrid Deployments
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Medtronic plc
  • 6.3.3 Boston Scientific Corporation
  • 6.3.4 BIOTRONIK SE & Co. KG
  • 6.3.5 MicroPort Scientific Corporation
  • 6.3.6 Implicity
  • 6.3.7 Vector Remote Care
  • 6.3.8 Canary Medical Inc.
  • 6.3.9 Zimmer Biomet Holdings, Inc.
  • 6.3.10 Stryker Corporation
  • 6.3.11 Smith & Nephew plc
  • 6.3.12 LifeOmic
  • 6.3.13 Welkin Health
  • 6.3.14 Koninklijke Philips N.V.
  • 6.3.15 Veeva Systems Inc.
  • 6.3.16 Castor
  • 6.3.17 Bioexcel Life Sciences
  • 6.3.18 NeuroPace, Inc.
  • 6.3.19 CVRx, Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment
• 7.2 Future Outlook